PTAB institutes four IPRs against Janssen Simponi patents in biosimilar dispute

PTAB Director instituted four inter partes reviews challenging Janssen's Simponi golimumab patents brought by biosimilar makers Accord and Bio-Thera, tied to ongoing BPCIA litigation with $1.2B at stake.